跳转至内容
Merck
CN

SML0356

Etonogestrel

≥98% (HPLC)

别名:

(17α)-13-Ethyl-17-hydroxy-11-methylene-18,19-dinorpregn-4-en-20-yn-3-one, 3-Keto-desogestrel, 3-Oxo-desogestrel

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式(希尔记法):
C22H28O2
化学文摘社编号:
分子量:
324.46
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
51111800
EC Number:
258-936-2
MDL number:
Assay:
≥98% (HPLC)
Form:
powder
Quality level:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

Quality Level

assay

≥98% (HPLC)

form

powder

optical activity

[α]/D +80 to +95°, c = 1 (CHCl3)

color

white to beige

solubility

DMSO: >5 mg/mL

storage temp.

−20°C

SMILES string

CC[C@]12CC(=C)[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C

InChI

1S/C22H28O2/c1-4-21-13-14(3)20-17-9-7-16(23)12-15(17)6-8-18(20)19(21)10-11-22(21,24)5-2/h2,12,17-20,24H,3-4,6-11,13H2,1H3/t17-,18-,19-,20+,21-,22-/m0/s1

InChI key

GCKFUYQCUCGESZ-BPIQYHPVSA-N

Gene Information

human ... PGR(5241)

正在寻找类似产品? 访问 产品对比指南

Biochem/physiol Actions

Etonogestrel is a lipophilic molecule. Pharmacokinetics studies reveal that etonogestrel is bound to protein albumin in the blood. This remains independent of both endogenous and exogenous concentration of estradiol.
Etonogestrel is a progestin, contraceptive.
Etonogestrel is a third-generation progestin contraceptive. Etonogestrel is used as a contraceptive itself and is also the active metabolite of the drug desogestrel used in some combination contraceptives.

Features and Benefits

This compound is featured on the Nuclear Receptors (Steroids) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

pictograms

Health hazard

signalword

Danger

hcodes

Hazard Classifications

Carc. 2 - Repr. 1B

存储类别

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

法规信息

新产品

此项目有


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Diana Mansour et al.
Contraception, 83(3), 202-210 (2011-02-12)
The aim of this guidance is to review the management of unacceptable vaginal bleeding patterns in etonogestrel (ENG)-releasing contraceptive implant users concentrating, where possible, on the evidence for pharmacological treatments and identifying a pragmatic approach where this is not possible.
Anne Calhoun et al.
Headache, 52(8), 1246-1253 (2012-07-14)
To determine whether extended-cycle dosing of an ultralow dose vaginal ring contraceptive decreases frequency of migraine aura and prevents menstrual related migraine (MRM). Many women are denied therapy with combined hormonal contraceptives due to published guidelines that recommend against their
Hanna Xu et al.
Obstetrics and gynecology, 120(1), 21-26 (2012-06-09)
To estimate the contraceptive failure rates of the etonogestrel subdermal contraceptive implant in overweight and obese women and compare failure rates with women of normal weight and women using intrauterine devices (IUDs). The Contraceptive CHOICE Project is a large prospective
Milena B Brito et al.
Thrombosis research, 130(3), 355-360 (2012-05-01)
The puerperium is the period of highest risk for thrombosis during a woman's reproductive life and it is an important time for initiating an effective contraceptive method in order to increase intergestational interval. Thus, the objective of the present study
Matthew Brown et al.
Contraception, 86(5), 591-593 (2012-07-10)
The etonogestrel contraceptive implant (Implanon®) is an effective, long-acting subdermal method of hormonal contraception for women. We describe a case of forearm pain and hypoesthesia associated with the insertion of the Implanon® contraceptive implant in a healthy 26-year-old female. These

商品

We offers many products related to Nuclear Receptors (Steroids) for your research needs.

我们可提供多种核受体(类固醇)相关产品,满足您的各类研究需求。

全球贸易项目编号

货号GTIN
SML0356-25MG04061832867984
SML0356-5MG04061832867991

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持